Top-Line Results Of Boceprevir Phase II Study Showed High Rate Of Sustained Response (SVR) In Genotype 1 Treatment-Naive Hepatitis C Patients Schering-Plough Corporation (NYSE: SGP) reported top-line results from a planned interim analysis of a Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The analysis showed a high rate of sustained virologic response (SVR) in patients receiving boceprevir-based combination therapy in this study of 595 treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1.
Source: www.medicalnewstoday.comFDA Rejects Schering-Plough's Anaesthetic Drug Sugammadex NDA The U.S. FDA has issued a non-approvable letter to Schering-Plough regarding the U.S. firm's New Drug Application (NDA) for sugammadex sodium. The product (also marketed under the brand Bridion) is a selective relaxant binding agent that reverses the effects of neuromuscular blockade by rocuronium in general anaesthesia. In a press statement, Schering-Plough has said that the FDA's concerns over the drug are related to hypersensitivity or allergic reactions.
Source: www.medicalnewstoday.comThe Association Of Women's Health, Obstetric And Neonatal Nurses's Publication Wins Two Prestigious Awards The Association of Women's
Health, Obstetric and Neonatal Nurses (AWHONN) is proud to announce that its clinical practice journal, Nursing for Women's
Health, is the recipient of two awards. They are: The 2008 Publications Management Magnum Opus Award Each year, this contest is held to recognize excellence in custom publishing. Nursing for Women's
Health won the highest award, Gold, for "Best Overall Editorial.
Source: www.medicalnewstoday.comThe Future Of Pharma E-Marketing Challenges and opportunities for today's pharmaceutical e-marketers abound. From social networking tools and advanced physician portals to streaming video and closed loop strategies, the opportunities to open new communication channels with patients, physicians and other key stakeholders are limited only by a marketer's imagination and determination.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 PM
